片頭痛診療のルネッサンス

出版社: 医学と看護社
著者:
発行日: 2022-03-25
分野: 臨床医学:内科  >  脳神経科学/神経内科学
ISBN: 9784909888297
電子書籍版: 2022-03-25 (第1版第1刷)
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安:4~8営業日

4,180 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

4,180 円(税込)

商品紹介

頭痛診療の優れた戦略と、片頭痛のない生活を取り戻す新規治療薬をわかりやすく解説!

目次

  • 第1章 頭痛診療
    第2章 片頭痛の診断基準
    第3章 片頭痛の分類
    第4章 片頭痛の疫学
    第5章 片頭痛が及ぼすインパクト
    第6章 反復性片頭痛と慢性片頭痛
    第7章 片頭痛のスティグマ
    第8章 GPACとJPAC
    第9章 片頭痛の病態とCGRPの役割
    第10章 片頭痛の治療
     1. 急性期治療
     2. 予防療法
      1)抗てんかん薬
      2)β遮断薬
      3)Ca拮抗薬
      4)抗うつ薬
      5)アンギオテンシン変換酵素(ACE)阻害薬,アンギオテンシン II受容体遮断薬(ARB)
      6)その他の薬剤
    第11章 既存の予防療法の問題点
    第12章 CGRP
    第13章 CGRPの片頭痛に関係する知見
    第14章 CGRP関連薬剤
     1. CGRP受容体拮抗薬(gepant)
     2. CGRP関連抗体
      1)ガルカネズマブ
      2)エレヌマブ
      3)フレマネズマブ
      4)Eptinezumab
    第15章 最適使用推進ガイドライン
    第16章 CGRP関連新規片頭痛治療薬ガイドライン(暫定版)
    第17章 CGRP関連抗体の特定の背景を有する患者に関する注意点
    第18章 難治性片頭痛(refractory migrain; RM)
    第19章 CGRP関連抗体と既存の経口予防薬の併用
    第20章 薬剤の使用過多による頭痛(薬物乱用頭痛,medication overuse headache; MOH)の治療
    第21章 CGRPを標的にした抗体治療への期待と課題
    第22章 群発頭痛でのCGRP関連抗体の使用
    第23章 これからの新規治療薬

おすすめ商品

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

はじめに

P.12 掲載の参考文献
1) Sakai F, Igarashi H. Prevalence of migraine in Japan : a nationwide survey. Cephalalgia 1997 ; 17 : 15-22
2) GBD 2016 Disease and Injury Incidence and Prevalence Collaborator. Lancet 2017 ; 390 : 1211-1259

第1章 頭痛診療

P.14 掲載の参考文献
1) 竹島多賀夫, 菊井祥二. 【Common diseaseは神経学の主戦場である-現状と展望】頭痛. BRAIN and NERVE : 神経研究の進歩 2013 ; 65 : 1043-1055
2) 竹島多賀夫. 頭痛教育施設認定と頭痛センター-地域頭痛教育センターの立場から. 日本頭痛学会誌 2021 ; 48 : 115-119
P.16 掲載の参考文献
1) Do TP, Remmers A, Schytz HW, et al. Red and orange flags for secondary headaches in clinical practice : SNNOOP10 list. Neurology 2019 ; 92 : 134-144
2) 頭痛の診療ガイドライン作成委員会編. 日本神経学会, 日本頭痛学会, 日本神経治療学会監修. 頭痛の診療ガイドライン 2021, 医学書院 ; 2021
3) 竹島多賀夫, 菊井祥二. 【Common diseaseは神経学の主戦場である-現状と展望】頭痛. BRAIN and NERVE : 神経研究の進歩 2013 ; 65 : 1043-1055
P.20 掲載の参考文献
1) The Headache Classification Committee of the International Headache Society (IHS). Cephalalgia 2018 ; 38 : 1-211
2) Jordan JE, Flanders AE. Headache and neuroimaging : why we continue to do it. AJNR 2020 ; 41 : 1149-1155

第2章 片頭痛の診断基準

P.23 掲載の参考文献
1) Headache Classification committee of the International Headache Society. Cephalalgia 1988 ; 8 (Suppl 7) : 1-96
2) Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders : 2 nd edition. Cephalalgia 2004 ; 24 (Suppl 1) : 9-160
3) Headache Classification Committee of the International Headache Society. Cephalalgia 2013 ; 33 : 629-808
4) 清水利彦, 柴田護, 永田栄一郎, 他. 国際頭痛分類 第3版 (ICHD-3) における主要な改訂点. 日本頭痛学会誌 2018 ; 45 : 148-159

第4章 片頭痛の疫学

P.27 掲載の参考文献
1) Woldeamanuel YW, Cowan RP. Migraine affects 1 in 10 people worldwide featuring recent rise : A systematic review and meta-analysis of community-based studies involving 6 million participants. J Neurol Sci 2017 ; 372 : 307-315
2) Sakai F, Igarashi H. Prevalence of migraine in Japan : a nationwide survey. Cephalalgia 1997 ; 17 : 15-22
3) Takeshima T, Ishizaki K, Fukuhara Y, et al. Population-based door-to-door survey of migraine in Japan : the Daisen study. Headache 2004 ; 44 : 8-19

第5章 片頭痛が及ぼすインパクト

P.30 掲載の参考文献
1) 竹島多賀夫, 房安恵美, 中島健二. 頭痛臨床の進歩 京都頭痛宣言-頭痛医療の充実に向けて. 日本医事新報 2005 ; 4258 : 31-32
2) Kikui S, Chen Y, Todaka H, et al. Burden of migraine among Japanese patients : a cross-sectional National Health and Wellness Survey. J Headache Pain 2020 ; 21 : 110

第6章 反復性片頭痛と慢性片頭痛

P.34 掲載の参考文献
1) 粟木悦子, 清水利彦, 五十嵐久佳, 他. International Classification of Headache Disorders 4 th alpha (ICHD-4α) "episodic migraine" の暫定定義と "premonitory/prodrome" の用語解釈について. 日本頭痛学会誌 2021 ; 47 : 317-319
2) Natoli JL, Manack A, Dean B, et al. Global prevalence of chronic migraine : A systematic review. Cephalalgia 2010 ; 30 : 599-609
3) Bigal ME, Lipton RB. Concepts and mechanisms of migraine chronification. Headache 2008 ; 48 : 7-15
4) Manack A, Buse DC, Serrano D, et al. Rates, predictors, and consequences of remission from chronic migraine to episodic migraine. Neurology 2011 ; 76 : 711-718
5) Bigal ME, Lipton RB. Clinical course in migraine : Conceptualizing migraine transformation. Neurology 2008 ; 71 : 848-855
6) Lipton RB, Fanning KM, Serrano D, et al. Ineffective acute treatment of episodic migraine is associated with new-onset chronic migraine. Neurology 2015 ; 84 : 688-695
7) Pagnini P, Vannucchi P, Giannoni B, et al. Epigone migraine vertigo (EMV) : a late migraine equivalent. Acta Otorhinolaryngol Ital 2014 ; 34 : 62-70

第7章 片頭痛のスティグマ

P.37 掲載の参考文献
1) アーヴイング ゴッフマン, 石黒毅 (訳). スティグマの社会-学烙印を押されたアイデンティティ-, せりか書房, 2001
2) 内潟安子.【糖尿病とスティグマ Cure, CareからSalvation (救済) へ】 語源, 歴史, 現状. 医学のあゆみ 2020 ; 273 : 150-153
3) Buse DC, Scher AI, Dodick DW, et al. Impact of Migraine on the Family : Perspectives of people with migraine and their spouse/domestic partner in the CaMEO Study. Mayo Clin Proc 2016 ; 91 : 596-611
4) Young W. The stigma of migraine. Pract Neurol 2018 ; 2 : 23-26 http://practicalneurology.com/2018/02/the-stigma-of-migraine. Accessed : July 7, 2021
5) Davidson L. The best excuses for calling in sick, according to your boss. 2020 https://www.telegraph.co.uk/education-and-careers/0/the-best-excuses-for-calling-in-sickaccording-to-your-boss/. Accessed 7 July 7, 2021
6) Lipton RB, Bigal ME, Rush SR, et al. Migraine practice patterns among neurologists. Neurology 2004 ; 62 : 1926-1931

第8章 GPACとJPAC

P.39 掲載の参考文献
1) Dodick D, Edvinsson L, Makino T, et al. Vancouver declaration on global headache patient advocacy 2018. Cephalalgia 2018 ; 38 : 1899-1909
2) Sakai F. Beat the stigma of primary headache disorders : Activities of JPAC and GPAC. Neurology and Clinical Neuroscience 2020 ; 8 : 128-131

第9章 片頭痛の病態とCGRPの役割

P.42 掲載の参考文献
1) Graham JR, Wolff HG. Mechanism of migraine headache and action of ergotamine tartrate. Arch Neurol Psychiatry 1938 ; 39 : 737-763
2) Olesen J, Friberg L, Olsen TS, et al. Timing and topography of cerebral blood flow, aura, and headache during migraine attacks. Ann Neurol 1990 ; 28 : 791-798
3) Olesen J, Larsen B, Lauritzen M. Focal hyperemia followed by spreading oligemia and impaired activation of rCBF in classic migraine. Ann Neurol 1981 ; 9 : 344-352
4) Hadjikhani N, del Rio MS, Wu O, et al. Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proc Natl Acad Sci USA 2001 ; 98 : 4687-4692
5) Moskowitz MA, Macfarlane R. Neurovascular and molecular mechanisms in migraine headaches. Cerebrovasc Brain Metab Rev 1984 ; 5 : 159-177
6) Moskowitz MA. The neurobiology of vascular head pain. Ann Neurol 1984 ; 16 : 157-168
7) Zagami AS, Goadsby PJ, Edvinsson L. Stimulation of the superior sagittal sinus in the cat causes release of vasoactive peptides. Neuropeptides 1990 ; 16 : 69-75
8) Tozzi A, de Iure A, di Filippo M, et al. Critical role of calcitonin gene-related peptide receptors in cortical spreading depression. Proc Natl Acad Sci USA 2012 ; 109 : 18985-18990
9) Edvinsson L. CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment. Br J Clin Pharmacol 2015 ; 80 : 193-199
10) Eftekhari S and Edvinsson L. Possible sites of action of the new calcitonin gene-related peptide receptor antagonists. Ther Adv Neurol Disord 2010 ; 3 : 369-378
11) Raddant AC and Russo AF. Calcitonin gene-related peptide in migraine : intersection of peripheral inflammation and central modulation. Expert Rev Mol Med 2011 ; 13 : e36
12) Karsan N and Goadsby PJ. CGRP mechanism antagonists and migraine management. Curr Neurol Neurosci Rep 2015 ; 15 : 25

第10章 片頭痛の治療

P.43 掲載の参考文献
1) Lipton RB, Silberstein SD. Episodic and chronic migraine headache : breaking down barriers to optimal treatment and prevention. Headache 2015 ; 55 (Suppl 2) : 103-122
P.49 掲載の参考文献
1) Lipton RB, Stewart WF, Stone AM, et al. Disabillity in Strategies of Care Study group. Stratified care vs step care strategies for migraine : The Disability in Strategies of Care (DISC) Study. A randomized trial. JAMA 2000 ; 284 : 2599-2605
2) 鈴木則宏. 内科疾患としての頭痛 ここまで進んだ病態解明と新規治療. 日本内科学会雑誌 2017 ; 106 : 1773-1780
3) 菊井祥二, 竹島多賀夫. 成熟したトリプタン治療も新規急性期治療薬の登場で変わるのか. 神経治療学 2020 ; 37 : 680-684
4) 竹島多賀夫, 菊井祥二, 山下晋.【頭痛update】片頭痛の治療 最近の進歩. 神経内科 2012 ; 77 : 359-367
5) 吉田雅博. 「根拠に基づく」から「GRADEシステム」へ. 肝胆膵 2018 ; 76 : 349-354

第11章 既存の予防療法の問題点

P.56 掲載の参考文献
1) Ueda K, Ye W, Lombard L, et al. Real-world treatment patterns and patient-reported outcomes in episodic and chronic migraine in Japan : analysis of data from the Adelphi migraine disease specific programme. J Headache Pain 2019 ; 20 : 68
2) Meyers JL, Davis KL, Lenz RA, et al. Treatment patterns and characteristics of patients with migraine in Japan : A retrospective analysis of health insurance claims data. Cephalagia 2019 ; 39 : 1518-1534

第12章 CGRP

P.58 掲載の参考文献
1) Amara SG, Jonas V, Rosenfeld MG, et al. Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products. Nature 1982 ; 298 : 240-244
2) Alevizaki M, Shiraishi A, Rassool FV, et al. The calcitonin-like sequence of the beta CGRP gene. FEBS Lett 1986 ; 206 : 47-52
3) Rosenfeld MG, Mermod JJ, Amara SG, et al. Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processing. Nature 1983 ; 304 : 129-135
4) Benarroch EE. CGRP : sensory neuropeptide with multiple neurologic implications. Neurology 2011 ; 77 : 281-287
5) Warfvinge K, Edvinsson L. Distribution of CGRP and CGRP receptor components in the rat brain. Cephalalgia 2019 ; 39 : 342-353
6) Kaiser EA, Russo AF. CGRP and migraine : could PACAP play a role too? Neuropeptides 2013 ; 47 : 451-461
7) Liang YL, Khoshouei M, Deganutti G, et al. Cryo-EM structure of the active, Gs-protein complexed, human CGRP receptor. Nature 2018 ; 561 : 492-497
8) Hay DL, Garelja ML, Poyner DR, et al. Update on the pharmacology of calcitonin/CGRP family of peptides : IUPHAR Review 25. Br J Pharmacol 2018 ; 175 : 3-17
9) Luebke AE, Dahl GP, Roos BA, et al. Identification of a protein that confers calcitonin gene-related peptide responsiveness to oocytes by using a cystic fibrosis transmembrane conductance regulator assay. Proc Natl Acad Sci USA 1996 ; 93 : 3455-3460
10) Han JS, Li W, Neugebauer V. Critical role of calcitonin gene-related peptide 1 receptors in the amygdala in synaptic plasticity and pain behavior. J Neurosci 2005 ; 25 : 10717-10728
11) Okutsu Y, Takahashi Y, Nagase M, et al. Potentiation of NMDA receptor-mediated synaptic transmission at the parabrachial-central amygdala synapses by CGRP in mice. Mol Pain 2017 ; 13 : 1744806917709201

第13章 CGRPの片頭痛に関係する知見

P.60 掲載の参考文献
1) Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 1990 ; 28 : 183-187
2) Ho TW, Edvinsson L, Goadsby PJ. CGRP and its receptors provide new insights into migraine pathophysiology. Nat Rev Neurol 2010 ; 6 : 573-582
3) Tfelt-Hansen P, Le H. Calcitonin gene-related peptide in blood : is it increased in the external jugular vein during migraine and cluster headache? a review. J Headache Pain 2009 ; 10 : 137-143
4) Ashina M, Bendtsen L, Jensen R, et al. Evidence for increased plasma levels of calcitonin gene-related peptide in migraine outside of attacks. Pain 2000 ; 86 : 133-138
5) Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine : studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 1993 ; 33 : 48-56
6) Lassen LH, Haderslev PA, Jacobsen VB, et al. CGRP may play a causative role in migraine. Cephalalgia 2002 ; 22 : 54-61
7) Hansen JM, Hauge AW, Olesen J, et al. Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura. Cephalalgia 2010 ; 30 : 1179-1186

第14章 CGRP関連薬剤

P.64 掲載の参考文献
1) Olesen J, Diener HC, Husstedt IW, et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 2004 ; 350 : 1104-1110
2) Connor KM, Shapiro RE, Diener H-C, et al. Randomized, controlled trial of telcagepant for the acute treatment of migraine. Neurology 2009 ; 73 : 970-977
3) Ho TW, Ferrari MD, Dodick DW, et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine : a andomized, placebo-controlled, parallel-treatment trial. Lancet 2008 ; 372 : 2115-2123
4) Schuster NM, Rapoport AM. Calcitonin gene-related peptide-targeted therapies for migraine and cluster headache : a review. Clin Neuropharmacol 2017 ; 40 : 169-174
5) Dodick DW, Lipton RB, Ailani J, et al. Ubrogepant for the treatment of migraine. N Engl J Med 2019 ; 381 : 2230-2241
6) Lipton RB, Dodick DW, Ailani J, et al. Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine : the ACHIEVE II randomized clinical trial. JAMA 2019 ; 322 : 1887-1898
7) Lipton RB, Croop R, Stock EG, et al : Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine. N Engl J Med 2019 ; 381 : 142-149
8) Croop R, Goadsby PJ, Stock DA, et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine : a randomised, phase 3, double-blind, placebo-controlled trial. Lancet 2019 ; 394 : 737-745
9) Croop R, Lipton RB, Kudrow D, et al. Oral rimegepant for preventive treatment of migraine : a phase 2/3, randomised, double-blind, placebo-controlled trial. Lancet 2021 ; 397 : 51-60
10) Goadsby PJ, Dodick DW, Ailani J, et al. Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults : a double-blind, randomised phase 2 b/3 trial. Lancet Neurol 2020 ; 19 : 727-737
P.76 掲載の参考文献
1) Stauffer VL, Dodick DW, Zhang Q, et al. Evaluation of galcanezumab for the prevention of episodic migraine : the EVOLVE-1 randomized clinical trial. JAMA Neurol 2018 ; 75 : 1080-1088
2) Skljarevski V, Matharu M, Millen BA, et al. Efficacy and safety of galcanezumab for the prevention of episodic migraine : results of the EVOLVE-2 phase 3 randomized controlled clinical trial. Cephalalgia 2018 ; 38 : 1442-1454
3) Detke HC, Goadsby PJ, Wang S, et al. Galcanezumab in chronic migraine : The randomized, double-blind, placebo-controlled REGAIN study. Neurology 2018 ; 91 : e2211-e2221
4) Mulleners WM, Kim BK, Lainez MJA, et al. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER) : a multicentre, randomised, double-blind, placebo-controlled, phase 3 b trial. Lancet Neurol 2020 ; 19 : 814-825
5) Sakai F, Ozeki A, Skljarevski V. Efficacy and safety of galcanezumab for prevention of migraine headache in Japanese patients with episodic migraine : A phase 2 randomized controlled clinical trial. Cephalalgia Reports 2020 ; 3 : 1-10
6) Goadsby PJ, Reuter U, Hallstrom Y, et al. A Controlled Trial of erenumab for episodic migraine. N Engl J Med 2017 ; 377 : 2123-2132
7) Goadsby PJ, Reuter U, Hallstrom Y, et al. One-year sustained efficacy of erenumab in episodic migraine : Results of the STRIVE study. Neurology 2020 ; 95 : e469-e479
8) Dodick DW, Ashina M, Brandes JL, et al. ARISE : a phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia 2018 ; 38 : 1026-1037
9) Reuter U, Goadsby PJ, Lanteri-Minet M, et al. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful : a randomised, double blind, placebo-controlled, phase 3b study. Lancet 2018 ; 392 : 2280-2287
10) Tepper S, Ashina M, Reuter U, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine : a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol 2017 ; 16 : 425-434
11) Ashina M, Goadsby PJ, Reuter U, et al. Long-term efficacy and safety of erenumab in migraine prevention : Results from a 5-year, open-label treatment phase of a randomized clinical trial. Eur J Neurol 2021 ; 28 : 1716-1725
12) Sakai F, Takeshima T, Tatsuoka Y, et al. A randomized phase 2 study of erenumab for the prevention of episodic migraine in Japanese adults. Headache 2019 ; 59 : 1731-1742
13) Takeshima T, Sakai F, Hirata K, et al. Erenumab treatment for migraine prevention in Japanese patients : Efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled study. Headache 2021 ; 61 : 927-935
14) Dodick DW, Silberstein SD, Bigal ME, et al. Effect of fremanezumab compared with placebo for prevention of episodic migraine : a randomized clinical trial. JAMA 2018 ; 319 : 1999-2008
15) Silberstein SD, Dodick DW, Bigal ME, et al. Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med 2017 ; 377 : 2113-2122
16) Ferrari MD, Diener HC, Ning X, et al. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS) : a randomised, double blind, placebo-controlled, phase 3b trial. Lancet 2019 ; 394 : 1030-1040
17) Sakai F, Suzuki N, Kim BK, et al. Efficacy and safety of fremanezumab for episodic migraine prevention : Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients. Headache 2021 ; 61 : 1102-1111
18) Sakai F, Suzuki N, Kim BK, et al. Efficacy and safety of fremanezumab for chronic migraine prevention : Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients. Headache 2021 ; 61 : 1092-1101
19) Ashina M, Saper J, Cady R, et al. Eptinezumab in episodic migraine : a randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia 2020 ; 40 : 241-254
20) Lipton RB, Goadsby PJ, Smith J, et al. Efficacy and safety of eptinezumab in patients with chronic migraine : PROMISE-2. Neurology 2020 ; 94 : e1365-e1377

第15章 最適使用推進ガイドライン

P.80 掲載の参考文献
1) 最適使用推進ガイドライン ガルカネズマブ (遺伝子組換え) https://www.pmda.go.jp/files/000240430.pdf
2) 最適使用推進ガイドライン エレヌマブ (遺伝子組換え) https://www.pmda.go.jp/files/000242834.pdf
3) 最適使用推進ガイドライン フレマネズマブ (遺伝子組換え) https://www.pmda.go.jp/files/000242836.pdf

第16章 CGRP関連新規片頭痛治療薬ガイドライン ( 暫定版 )

P.85 掲載の参考文献
1) CGRP関連新規片頭痛治療薬ガイドライン (暫定版) https://www.jhsnet.net/guideline_CGRP.html

第17章 CGRP関連抗体の特定の背景を有する患者に関する注意点

P.88 掲載の参考文献
1) Noseda R, Bedussi F, Gobbi C, et al. Safety profile of erenumab, galcanezumab and fremanezumab in pregnancy and lactation : Analysis of the WHO pharmacovigilance database. Cephalalgia 2021 ; 41 : 789-798
2) エムガルティ(R) 皮下注120 mg オートインジェクター, エムガルティ(R) 皮下注120 mg シリンジ 添付文書 2021年4月改訂 (第3版)
3) アイモビーグ(R) 皮下注70 mg ペン添付文書 2021年6月改訂 (第1版)
4) アジョビ(R) 皮下注225 mg シリンジ添付文書 2021年6月改訂 (第1版)
5) Sacco S, Bendtsen L, Ashina M, et al. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain 2019 ; 20 : 6
6) 平成 29年6月8日付け薬生発 0608 第1号 厚生労働省医薬・生活衛生局長通知「医療用医薬品の添付文書等の記載要領の留意事項について」 https://www.pmda.go.jp/files/000218448.pdf
7) 竹島多賀夫, 福原葉子, 中島健二. 【トリプタン治療最前線】特殊な片頭痛患者におけるトリプタン使用の是非 片麻痺性片頭痛, 脳底型片頭痛など. 医学のあゆみ 2003 ; 204 : 483-487

第18章 難治性片頭痛 ( refractory migrain ; RM )

P.93 掲載の参考文献
1) Reisman EE Jr. The use of experimental suppositories in treating refractory migraine. Am Pract Dig Treat 1952 ; 3 : 308-310
2) Goadsby PJ, Schoenen J, Ferrari MD, et al. Towards a definition of intractable headache for use in clinical practice andtrials. Cephalalgia 2006 ; 26 : 1168-1170
3) Schulman EA, Lake AE 3 rd, Goadsby PJ, et al. Defining refractory migraine and refractory chronic migraine : proposed criteria from the refractory headache special interest section of the American headache society. Headache 2008 ; 48 : 778-782
4) Silberstein SD, Dodick DW, Pearlman S. Defining the pharmacologically intractable headache for clinical trials and clinical practice. Headache 2010 ; 50 : 1499-1506
5) Martelletti P, Katsarava Z, Lampl C, et al. Refractory chronic migraine : a consensus statement on clinical definition from the European headache federation. J Headache Pain 2014 ; 15 : 47.
6) D'Antona L, Matharu M. Identifying and managing refractory migraine : barriers and opportunities? J Headache Pain 2019 ; 20 : 89
7) Sacco S, Braschinsky M, Ducros A, et al. European headache federation consensus on the definition of resistant and refractory migraine : Developed with the endorsement of the European Migraine & Headache Alliance (EMHA). J Headache Pain 2020 ; 21 : 76

第20章 薬剤の使用過多による頭痛 ( 薬物乱用頭痛, medication overuse headache; MOH ) の治療

P.96 掲載の参考文献
1) 頭痛の診療ガイドライン作成委員会編. 日本神経学会, 日本頭痛学会, 日本神経治療学会監修. 頭痛の診療ガイドライン 2021, 医学書院 ; 2021
2) Tepper SJ, Diener H-C, Ashina M, et al. Erenumab in chronic migraine with medication overuse : Subgroup analysis of a randomized trial. Neurology 2019 ; 92 : e2309-e2320
3) Dodick DW, Doty EG, Aurora SK, et al. Medication overuse in a subgroup analysis of phase 3 placebo-controlled studies of galcanezumab in the prevention of episodic and chronic migraine. Cephalalgia 2021 ; 41 : 340-352
4) Silberstein SD, Cohen JM, Seminerio MJ, et al. The impact of fremanezumab on medication overuse in patients with chronic migraine : subgroup analysis of the HALO CM study. J Headache Pain 2020 ; 21 : 114
5) Diener H-C, Marmura MJ, Tepper SJ, et al. Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication-overuse headache : Subgroup analysis of PROMISE-2. Headache 2021 ; 61 : 125-136
6) 團野大介, 菊井祥二, 竹島多賀夫. 新しい頭痛発症抑制薬「抗CGRPモノクローナル抗体」による片頭痛治療-ガルカネズマブ発売後早期のリアルワールドデータ. 日本医事新報 2021 ; 5092 : 34-37
7) 菊井祥二, 團野大介, 竹島多賀夫. 新しい頭痛発症抑制薬「抗CGRPモノクローナル受容体阻害薬」による片頭痛治療-エレヌマブ発売後早期のリアルワールドデータ 日本医事新報 2022 ; (印刷中)

第21章 CGRPを標的にした抗体治療への期待と課題

P.100 掲載の参考文献
1) 團野大介, 菊井祥二, 竹島多賀夫. 新しい頭痛発症抑制薬「抗CGRPモノクローナル抗体」による片頭痛治療-ガルカネズマブ発売後早期のリアルワールドデータ 日本医事新報 2021 ; 5092 : 34-37
P.101 掲載の参考文献
1) Raffaelli B, Terhart M, Overeem LH, et al. Migraine evolution after the cessation of CGRP (-receptor) antibody prophylaxis : a prospective, longitudinal cohort study. Cephalalgia. 2021 Sep 27 : 3331024211046617. doi : 10.1177/03331024211046617. Epub ahead of print.
P.103 掲載の参考文献
1) Robblee J, Devick KL, Mendez N, et al. Real-world patient experience with erenumab for the preventive treatment of migraine. Headache 2020 ; 60 : 2014-2025
2) Kanaan S, Hettie G, Loder E, et al. Real-world effectiveness and tolerability of erenumab : a retrospective cohort study. Cephalalgia 2020 ; 40 : 1511-1522
P.104 掲載の参考文献
1) Patier Ruiz I, Sanchez-Rubio Ferrandez J, Carcamo Fonfria A, et al. Early Experiences in Switching between Monoclonal Antibodies in Patients with Nonresponsive Migraine in Spain : A Case Series. Eur Neurol 2021 ; 10 : 1-4
2) Overeem LH, Andreas Peikert A, Hofacker MD, et al. Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine : A multi-center retrospective cohort study. Cephalalgia 2021 : 3331024211048765
3) 菊井祥二, 團野大介, 竹島多賀夫. 新しい頭痛発症抑制薬「抗CGRPモノクローナル受容体阻害薬」による片頭痛治療-エレヌマブ発売後早期のリアルワールドデータ 日本医事新報 2022 ; (印刷中)

第22章 群発頭痛でのCGRP関連抗体の使用

P.107 掲載の参考文献
1) Goadsby PJ, Edvinsson L. Human in vivo evidence for trigeminovascular activation in cluster headache. Neuropeptide changes and effects of acute attacks therapies. Brain 1994 ; 117 : 427-434
2) Goadsby PJ, Dodick DW, Leone M, et al. Trial of galcanezumab in prevention of episodic cluster headache. N Engl J Med 2019 ; 381 : 132-141
3) Dodick DW, Goadsby PJ, Lucas C, et al. Phase 3 randomized, placebo-controlled study of galcanezumab in patients with chronic cluster headache : results from 3-month double-blind treatment. Cephalalgia 2020 ; 40 : 935-948
4) Ruscheweyh R, Broessner G, Gosrau G, et al. Effect of calcitonin gene-related peptide (-receptor) antibodies in chronic cluster headache : results from a retrospective case series support individual treatment attempts. Cephalalgia 2020 ; 40 : 1574-1584

第23章 これからの新規治療薬

P.109 掲載の参考文献
1) Nelson DL, Phebus LA, Johnson KW, et al. Preclinical pharmacological profile of the selective 5-HT1 F receptor agonist lasmiditan. Cephalalgia 2010 ; 30 : 1159-1169
2) Oswald JC, Schuster NM. Lasmiditan for the treatment of acute migraine : a review and potential role in clinical practice. J Pain Res 2018 ; 11 : 2221-2227
3) Kuca B, Silberstein SD, Wietecha L, et al. Lasmiditan is an effective acute treatment for migraine : a phase 3 randomized study. Neurology 2018 ; 91 : e2222-e2232
4) Goadsby PJ, Wietecha LA, Dennehy EB, et al. Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain 2019 ; 142 : 1894-1904
5) Shapiro RE, Hochstetler HM, Dennehy EB, et al. Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors : Post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 Trials. J Headache Pain 2019 ; 20 : 90
6) Doty EG, Krege JH, Jin L, et al. Sustained responses to lasmiditan : results from post-hoc analyses of two phase 3 randomized clinical trials for acute treatment of migraine. Cephalalgia 2019 ; 39 : 1569-1576
7) Loo LS, Ailani J, Schim J, et al. Efficacy and safety of lasmiditan in patients using concomitant migraine preventive medications : Findings from SAMURAI and SPARTAN, two randomized phase 3 trials. J Headache Pain 2019 ; 20 : 84
8) Loo LS, Plato BM, Turner IM, et al. Effect of a rescue or recurrence dose of lasmiditan on efficacy and safety in the acute treatment of migraine : Findings from the phase 3 trials (SAMURAI and SPARTAN). BMC Neurology 2019 ; 19 : 191
9) Brandes JL, Klise S, Krege JH, et al. Interim results of a prospective, randomized, openlabel, phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (The GLADIATOR Study). Cephalalgia 2019 ; 39 : 1343-1357
P.110 掲載の参考文献
1) Miyata A, Arimura A, Dahl RR, et al. Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem Biophys Res Commun 1989 ; 164 : 567-574
2) Schytz HW, Birk S, Wienecke T, et al. PACAP38 induces migraine-like attacks in patients with migraine without aura. Brain 2009 ; 132 : 16-25
3) Rustichelli C, Lo Castro F, Baraldi C, et al. Targeting pituitary adenylate cyclaseactivating polypeptide (PACAP) with monoclonal antibodies in migraine prevention : a brief review. Expert Opin Investig Drugs 2020 ; 29 : 1269-1275

最近チェックした商品履歴

Loading...